Sirtris Pharmaceuticals, Inc. (NASDAQ: SIRT), a biopharmaceutical company focused on discovering and developing small molecule drugs to treat diseases of aging such as Type 2 Diabetes, announced today that Chief Executive Officer and Vice Chair Christoph Westphal, M.D., Ph.D.

By FRANK QUARATIELLO Cambridge-based Sirtris Pharmaceuticals yesterday announced strong positive results from an early-stage clinical trial targeting type 2 diabetes for a drug based on resveratrol, a chemical found in red wine.

By FRANK QUARATIELLO When Sirtris Pharmaceuticals met with New York investors earlier this year and word got out that Red Sox owner John Henry had invested in the company, some of the deep-pocketed Yankees fans joked that the high-flying Sox at the time must be using resveratrol.

Sirtris Pharmaceuticals, the leading sirtuin therapeutics company, announced today that Sirtris CEO, Christoph Westphal, M.D., Ph.D.

Sirtris Pharmaceuticals, Inc., the leading sirtuin therapeutics company, announced the hiring of Mike Jirousek, Ph.D. as Senior Vice President of Research. Dr. Jirousek has worked in the pharmaceutical industry with a focus on drug discovery for more than fifteen years.